Mirum Pharmaceuticals has received U.S. FDA approval for Atebrioz (zilurgisertib), a once-daily oral treatment for fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder in which muscles, tendons and other soft tissues progressively turn into bone. The approval gives patients ages 12 and older another treatment option for a disease affecting approximately 300 people in the United States and 900 worldwide.
The approval also intensifies competition in the rare-disease pharmaceutical market. Mirum’s Atebrioz joins treatments from Regeneron Pharmaceuticals and Ipsen, with Atebrioz and Regeneron’s Pasatru targeting different components of the same biological pathway involved in abnormal bone formation. Atebrioz’s oral dosing and approval for both adolescents and adults could provide important differentiation as pharmaceutical companies compete to address the needs of patients with FOP.
For pharmaceutical companies developing and commercializing therapies for ultra-rare diseases, success requires specialized leadership across clinical development, regulatory affairs, medical affairs, commercial strategy, market access and patient support. As the rare-disease pipeline continues to expand, experienced life sciences executives and specialized talent will remain critical to bringing innovative therapies to patients and successfully navigating increasingly competitive markets.
At The Bandish Group, we understand the specialized talent requirements of the pharmaceutical and biotech industries. Our executive search team connects companies with experienced leaders across pharmaceutical, biotechnology, medical affairs, clinical development, regulatory, commercial and other critical life sciences functions.
Click here to read the entire article.
